Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Notch Signaling Activity Determines Uptake and Biological Effect of Imatinib in Systemic Sclerosis Dermal Fibroblasts.

Harrach S, Barz V, Pap T, Pavenstädt H, Schlatter E, Edemir B, Distler J, Ciarimboli G, Bertrand J.

J Invest Dermatol. 2019 Feb;139(2):439-447. doi: 10.1016/j.jid.2018.08.021. Epub 2018 Sep 28.

PMID:
30273596
2.

Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.

Hinchcliff M, Huang CC, Ishida W, Fang F, Lee J, Jafari N, Wilkes M, Bhattacharyya S, Leof E, Varga J.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S86-96. Epub 2012 May 29. Erratum in: Clin Exp Rheumatol. 2014 Jan-Feb;32(1):150.

3.

MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients.

Harrach S, Schmidt-Lauber C, Pap T, Pavenstädt H, Schlatter E, Schmidt E, Berdel WE, Schulze U, Edemir B, Jeromin S, Haferlach T, Ciarimboli G, Bertrand J.

Blood Cancer J. 2016 Sep 16;6:e470. doi: 10.1038/bcj.2016.79.

4.

Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.

Pannu J, Asano Y, Nakerakanti S, Smith E, Jablonska S, Blaszczyk M, ten Dijke P, Trojanowska M.

Arthritis Rheum. 2008 Aug;58(8):2528-37. doi: 10.1002/art.23698.

5.

The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts.

Bujor AM, Asano Y, Haines P, Lafyatis R, Trojanowska M.

Arthritis Rheum. 2011 Jun;63(6):1729-37. doi: 10.1002/art.30284.

6.

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.

Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, Distler O, Distler JH.

Arthritis Rheum. 2009 Jan;60(1):219-24. doi: 10.1002/art.24186.

7.

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.

Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S, Distler O.

Arthritis Rheum. 2007 Jan;56(1):311-22.

8.

Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis.

Dees C, Tomcik M, Zerr P, Akhmetshina A, Horn A, Palumbo K, Beyer C, Zwerina J, Distler O, Schett G, Distler JH.

Ann Rheum Dis. 2011 Jul;70(7):1304-10. doi: 10.1136/ard.2010.134742. Epub 2011 Mar 30.

9.

Imatinib uptake into cells is not mediated by organic cation transporters OCT1, OCT2, or OCT3, but is influenced by extracellular pH.

Blanc Mettral J, Faller N, Cruchon S, Sottas L, Buclin T, Schild L, Choong E, Nahimana A, Decosterd LA.

Drug Metab Lett. 2019 Feb 7. doi: 10.2174/1872312813666190207150207. [Epub ahead of print]

PMID:
30734690
10.

Organic cation transporter 3 (OCT3/SLC22A3) and multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter in the placenta and fetal tissues: expression profile and fetus protective role at different stages of gestation.

Ahmadimoghaddam D, Zemankova L, Nachtigal P, Dolezelova E, Neumanova Z, Cerveny L, Ceckova M, Kacerovský M, Micuda S, Staud F.

Biol Reprod. 2013 Mar 7;88(3):55. doi: 10.1095/biolreprod.112.105064. Print 2013 Mar.

PMID:
23303678
11.

The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.

Misaka S, Knop J, Singer K, Hoier E, Keiser M, Müller F, Glaeser H, König J, Fromm MF.

Mol Pharm. 2016 Feb 1;13(2):512-9. doi: 10.1021/acs.molpharmaceut.5b00733. Epub 2016 Jan 19.

PMID:
26702643
12.

Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations.

König J, Zolk O, Singer K, Hoffmann C, Fromm MF.

Br J Pharmacol. 2011 Jun;163(3):546-55. doi: 10.1111/j.1476-5381.2010.01052.x.

13.

Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates.

van der Velden M, Bilos A, van den Heuvel JJMW, Rijpma SR, Hurkmans EGE, Sauerwein RW, Russel FGM, Koenderink JB.

Malar J. 2017 Oct 23;16(1):422. doi: 10.1186/s12936-017-2062-y.

14.

Attenuation of fibrosis with selective inhibition of c-Abl by siRNA in systemic sclerosis dermal fibroblasts.

Karimizadeh E, Motamed N, Mahmoudi M, Jafarinejad-Farsangi S, Jamshidi A, Faridani H, Gharibdoost F.

Arch Dermatol Res. 2015 Mar;307(2):135-42. doi: 10.1007/s00403-014-1532-0. Epub 2014 Dec 20.

PMID:
25527259
15.

Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis.

Schmidt-Lauber C, Harrach S, Pap T, Fischer M, Victor M, Heitzmann M, Hansen U, Fobker M, Brand SM, Sindic A, Pavenstädt H, Edemir B, Schlatter E, Bertrand J, Ciarimboli G.

PLoS One. 2012;7(12):e52247. doi: 10.1371/journal.pone.0052247. Epub 2012 Dec 20.

16.

Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine.

Müller F, König J, Hoier E, Mandery K, Fromm MF.

Biochem Pharmacol. 2013 Sep 15;86(6):808-15. doi: 10.1016/j.bcp.2013.07.008. Epub 2013 Jul 20.

PMID:
23876341
17.

Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.

Akamata K, Asano Y, Aozasa N, Noda S, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Sato S.

Arthritis Res Ther. 2014 Apr 3;16(2):R86. doi: 10.1186/ar4529.

18.

Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms.

Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB.

Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005. doi: 10.1152/ajprenal.00431.2009. Epub 2010 Jan 6.

19.

Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins.

Minematsu T, Giacomini KM.

Mol Cancer Ther. 2011 Mar;10(3):531-9. doi: 10.1158/1535-7163.MCT-10-0731. Epub 2011 Jan 20.

20.

Increased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor β.

Piera-Velazquez S, Makul A, Jiménez SA.

Arthritis Rheumatol. 2015 Oct;67(10):2749-58. doi: 10.1002/art.39242.

Supplemental Content

Support Center